In this Supplement
The Rise of Peripheral Drug Elution
How to incorporate drug-coated balloons and drug-eluting stents into your practice.
Drug Elution, Data, and Decisions
What the data tell us about how to integrate drug-eluting technology into our daily practice.
By Gary Ansel, MD, and John A. Phillips, MD
An Overview of Superficial Femoral Artery Stenting
The history, data, and latest advancements in stenting of the SFA and popliteal arteries.
By John R. Laird, MD, and Ehrin J. Armstrong, MD
Zilver PTX for Simple and Challenging Lesions
How I integrate this versatile tool into my lower extremity practice.
By William A. Gray, MD
DCBs in the United States
The use of drug-coated balloons is creating a paradigm shift in the treatment of peripheral arterial disease by preventing restenosis and leaving nothing behind.
By George L. Adams, MD, MHS, and O Jesse Mendes, BA
DES and DEB Use in Europe
As devices develop and longer follow-up data become available, one thing is certain: It’s a drug-eluting world, all right.
By Konstantinos Katsanos, MSc, MD, PhD, EBIR
The Costs and Benefits of Medical Innovation
Looking beyond prices and assessing the true value of new technologies.
By Louis L. Nguyen, MD, MBA, MPH, and Rebecca E. Scully, MD
DES Versus Bypass for Femoropopliteal Disease
Should the current data on drug-eluting devices cause surgeons to reconsider when to use bypass?